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Tubedown-1 (tbdn-1) is a mammalian homologue of the N-terminal acetyltransferase subunit NAT1 of Saccharomyces
cerevisiae and copurifies with an acetyltransferase activity. Tbdn-1 expression in endothelial cells becomes downregulated
during the formation of capillary-like structures in vitro and is regulated in vivo in a manner which suggests a functional
role in dampening blood vessel development. Here we show that tbdn-1 is expressed highly in the vitreal vascular network
(tunica vasculosa lentis and vasa hyaloidea propria) during the pruning and remodeling phases of this transient structure.
The vitreal blood vessels of mice harboring a targeted inactivation of TGF-2 fail to remodel and abnormally accumulate,
a phenomenon reminiscent of the ocular pathology resembling persistent fetal vasculature (PFV) in humans. Since
suppression of normal tbdn-1 expression has been previously observed in retinal vessel proliferation, we analyzed vitreal
vascular changes and tbdn-1 expression in TGF-2/ eyes. The nuclei of vitreal vessel endothelial cells in TGF-2/ eyes
express proliferating cell nuclear antigen (PCNA) and exhibit increased levels of active P42/44mitogen-activated protein kinase
(phospho-P42/44MAPK), characteristics consistent with proliferative endothelial cells. In contrast to normal vitreal vessels,
collagen IV expression exhibited a disorganized pattern in the TGF-2/ vitreal vessels, suggesting vessel disorganization
and possibly a breakdown of vessel basal laminae. Moreover, vitreal vessels of TGF-2/ mice lack expression of pericyte
markers (CD13, alpha smooth muscle actin) and show ultrastructural changes consistent with pericyte degeneration. The
accumulating vitreal blood vessels of TGF-2/ mice, while maintaining expression of the endothelial marker von
Willebrand Factor, show a significant decrease in the expression of tbdn-1. We addressed the functional role of tbdn-1 in the
regulation of vitreal blood vessels using an in vitro model of choroid–retina capillary outgrowth. Clones of the RF/6A fetal
choroid–retina endothelial cell line showing suppression of tbdn-1 levels after overexpression of an antisense TBDN-1
cDNA display a significant increase in the formation of capillary-like structures in vitro compared with controls. These
findings suggest that tbdn-1 inhibits capillary-like formation in vitro and may serve to dampen vitreal blood vessel
formation preceding the regression of the vitreal vasculature during development. Our results also suggest that tbdn-1 may
participate with TGF-2 in regulating normal development of the vitreal vasculature. © 2002 Elsevier Science (USA)
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In order to gain new insights into the processes control-
ling development and remodeling of the vasculature, we
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tubedown-1 (tbdn-1), which shows homology to yeast
NAT1, N-terminal acetyltransferase 1 subunit (Gendron et
al., 2000). Tbdn-1 copurifies with an acetyltransferase ac-
tivity, suggesting that tbdn-1 may serve a regulatory func-
tion by participating in the acetylation of other proteins.
Tbdn-1 is expressed in vascular structures during embryo-
genesis, and tbdn-1 protein expression is significantlyDevelopmental Biology 249, 140–155 (2002)
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tures by endothelial cells in vitro on Matrigel (Gendron et
al., 2000, 2001a). In adulthood in mice, expression of tbdn-1
is restricted to only a few tissues, including the ocular
endothelium, the bone marrow, blood vessels in regressing
ovarian follicles, and atrial endocardium. In human, the
suppression of normal retinal vascular tbdn-1 expression
has been observed in retinal vessel proliferation in prolif-
erative diabetic retinopathy (Gendron et al., 2001a).
During eye development, the posterior chamber (vitreal)
vasculature is composed of the hyaloid blood vessel net-
work (vasa hyaloidea propria), which extends in a network
of capillaries from the hyaloid artery at the posterior por-
tion of the eye and the tunica vasculosa lentis surrounding
the developing lens (Ito and Yoshioka, 1999). The develop-
ing vitreal vasculature can be viewed as a good in vivo
model of vascular remodeling, maturation, and regression
since it has a finite lifespan encompassing all of these
processes. In the mouse, the vitreal vasculature starts to
develop at E11.5 and matures and progressively regresses
almost to completion at approximately P10 (Mitchell et
al.,1998; Ito and Yoshioka, 1999; Zhu et al., 1999). The
vitreal vasculature temporarily nourishes posterior cham-
ber tissues. Formation and maturation of the vitreal vascu-
lature involves extensive initial vasculogenesis followed by
combinations of vasculogenesis and angiogenesis events
which are accompanied by pruning and remodeling of the
maturing vitreal vessel network (Lang et al., 1993; Yang et
al., 1996, Zhu et al., 1999; Mitchell et al.,1998; Ito and
Yoshioka, 1999; Ash and Overbeek, 2000). Both the matu-
ration and the regression processes of the vitreal vascula-
ture in the mouse are associated with apoptosis which
commences at approximately E17.5 (Lang et al., 1993;
Mitchell et al.,1998; Ito and Yoshioka, 1999; Ash and
Overbeek, 2000).
Persistent fetal vasculature (PFV; Goldberg, 1997) in-
cludes a number of vascular abnormalities, such as persis-
tent hyperplastic primary vitreous (PHPV), persistent pupil-
lary membrane, persistent iridohyaloid vessels, the
Mittendorf’s Dot, Bergmeister’s papilla, remnants of the
hyaloid artery, persistent vasa hyaloidea propria, and con-
genital nonattachment of the retina. PFV is characterized
by the failure of the hyaloid and tunica vasculosa lentis
vasculature to regress (Boeve et al., 1990; Steichen-Gersdorf
et al., 1997; Castillo et al., 1997; Goldberg, 1997; Silbert and
Gurwood, 2000). In the most severe form, this condition
can lead to vision loss and blindness. Several transgenic
mouse models display abnormalities of vitreal vascular
development and remodeling. Transgenic mice in which
ocular macrophages are disrupted display persistence of the
vitreal vasculature (Lang et al., 1993). A PFV-like condition
also develops in p53-deficient mice (Reichel et al., 1998).
Mice harboring specific NOTCH2 mutations display hyper-
plasia of cells associated with the hyaloid vasculature
(McCright et al., 2001). It was noticed that mice lacking
TGF-2 show abnormal accumulation of the developing
vitreal vasculature (Saika et al., 2001). However, the mo-
lecular and anatomical changes associated with accumula-
tion of vitreal vessels in TGF-2/ eyes have not yet been
characterized. To gain further insight into the role of tbdn-1
in the present work, we have analyzed the expression of
tbdn-1 in normal development of the vitreal vasculature
and in accumulated vitreal vessels of TGF-2/ eyes. We
have characterized in detail the cellular and structural
changes in the TGF-2/ vitreal vasculature. In addition,
the functional role of tbdn-1 in endothelial cells was inves-
tigated by evaluating its effects on the formation of
capillary-like structures by a fetal choroid–retina endothe-
lial cell line in vitro.
EXPERIMENTAL PROCEDURES
Immunohistochemistry
Immunohistochemistry was performed on paraformaldehyde-fixed,
paraffin-embedded sections of developing mouse tissue and human
eye specimens to detect tbdn-1 and other markers. The anti-tbdn-1
chicken IgY antibody (Ab1272) was described previously and was
proven useful for immunocytochemistry, Western blot, and immuno-
precipitation analysis (Gendron et al., 2000). All uses of mouse tissues
in this study were adherent to the Institute for Laboratory Animal
Research (Guide for the Care and Use of Laboratory Animals). Human
specimens were from autopsy material obtained postmortem from
consenting donors under the approval of the Institutional Review
Boards of the Smith Kettlewell Eye Research Institute, San Francisco
and Childrens Hospital Medical Center, Cincinnati. All research on
the human specimens followed the tenets of the Declaration of
Helsinki at all times. Reactions for tbdn-1 and negative control
chicken IgY preimmune staining were carried out by using modified
salt conditions in Tris-buffered saline (TBS) with 25 mM NaCl. All
other reactions were carried out in TBS with 150 mM NaCl. Follow-
ing a 1-h blocking step in 6% lowfat powdered milk in TBS, sections
were incubated with 1/200 dilutions of anti-tbdn-1 antibody Ab1272
(Gendron et al., 2000) or the preimmune IgY in 3% lowfat powdered
milk in TBS. The endothelial cell marker rabbit anti-von Willebrand
Factor (vWF) antibody (used undiluted; directly conjugated to peroxi-
dase; Dako, Denmark), the mouse monoclonal vascular smooth
muscle marker anti-alpha smooth muscle actin (ASMA) antibody
(dilution of 1/100; Sigma Immunochemicals, St. Louis, MI), mouse
monoclonal anti-CD13 (dilution of 1/50; clone SJ1D1 from Coulter
Immunology, Hialeah, FL), rabbit anti-phospho P42/44MAPK (dilution
of 1/500; New England Biolabs), rabbit anti-PCNA (dilution of 1/25;
Santa Cruz Biotechnology, Inc.), and the vascular wall basement
membrane marker anti-collagen IV antibody (dilution of 1/100; Saika
et al., 2001) were also used for labeling endothelial cells and vascular
wall structures in sections from blood vessels. The sections used for
staining vitreal structures were always taken from the same level, at
the eye equator, in order to maintain consistency in section locations
between eye specimens. After rinsing in the appropriate concentra-
tion of TBS, reactions were developed by using alkaline phosphatase-
conjugated species-specific secondary antibodies (anti-chicken IgY
second antibody reagents from Promega, Madison, WI, were also
incubated and washed in 25 mM NaCl TBS). Red color reactions for
tbdn-1 and ASMA staining were generated by using naphthol-AS-MX
Phosphate in the presence of Fast Red and Levamisole (to block
endogenous tissue alkaline phosphatase activity). Dark brown color
reactions for vWF staining were generated by using diaminobenzidine
(DAB) in the presence of hydrogen peroxide (sections were previously
pretreated with hydrogen peroxide to quench endogenous peroxidase
activity). Reacted sections were lightly counterstained by using a
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0.5% aqueous solution of methyl green, rinsed in water, dried, and
mounted in Permount (Fisher, Pittsburgh, PA). Sections were viewed
and photographed by using a Nikon microscope system with a Kodak
digital camera attachment.
Preparation and Analysis of TGF-2/ Mouse
Embryos
Wild type mouse embryos and mouse embryos either heterozy-
gous or homozygous null for a disrupted TGF-2 gene were
generated via gene targeting in 129-C57BL/6 mice and genotyped as
previously reported (Sanford et al., 1997). Tissue collection and
processing of wild type embryos and embryos from TGF2/ and
heterozygous littermates were also performed as previously de-
scribed (Saika et al., 2001). Five to ten embryos from each genotype
were morphologically and immunohistochemically analyzed.
Transmission Electron Microscopy
Transmission electron microscopy (TEM) was performed as
previously described (Saika et al., 2001). Briefly, both TGF2/ and
TGF2/ eyes from E18.5 stage were dehydrated and embedded in
Epon 812 mixture. Semithin sections were prepared and stained
with toluidine blue for inspection at 1000 high power by light
microscopy. Ultrathin sections were stained with electron dense
uranyl acetate and lead citrate, and vitreal tissues were observed
under TEM (Saika et al., 2001).
Cell Culture
IEM cells are an immortalized embryonic endothelial cell line
originally derived using differentiation products of mouse embry-
onic stem cells (Gendron et al., 1996). MK/T-1 cells are an
immortalized mouse fibroblast cell line derived using cultures of
mouse corneal stroma cells (Gendron et al., 2001b). Primary
culture of human umbilical vein endothelial cells (HUVEC) was
obtained from Clonetics (San Diego, CA). RF/6A cells (American
Type Culture Collection, Manassas, VA) are an immortalized
endothelial cell line derived from rhesus macaque fetal choroid–
retinal tissue (Lou and Hu, 1987a,b). BREC cells are primary bovine
retinal endothelial cells prepared as previously described (Schor and
Schor, 1986). Cells were grown and maintained in culture in low
glucose Dulbecco’s Modified Eagle Media (DMEM) supplemented
with 2 mM glutamine and either 10% (IEM, RF/6A, MK/T-1, and
HUVEC) or 5% (BREC) of fetal bovine serum (FBS). For RF/6A cells,
culture media was further supplemented with 50 M of nonessen-
tial amino acids, while HUVEC medium was supplemented with 1
ng/ml of bFGF and a mixture of insulin, transferrin, and selinium
(Gibco/BRL).
For treatment of RF/6A, HUVEC, BREC, and MK/T-1 cells with
TGF- in vitro, cells were cultured for 16–24 h in reduced FBS
(1%)-containing media and then stimulated for 24 and 48 h with 3
ng/ml of TGF-1 (R&D Systems, Minneapolis, MN).
Western Blotting
Western blotting analysis of whole cell lysates was performed by
standard procedures using chemiluminescence detection (ECL Plus
reagent; Amersham). Cell lysates were prepared by using Triton
X-100 lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton
X-100) supplemented with 1 mM DTT, protease inhibitors (1 mM
PMSF, 0.3 U/ml aprotinin, and 10 g/ml leupeptin) and phospha-
tase inhibitors (1 mM sodium orthovanadate, 25 mM sodium
fluoride, and 10 mM -glycerophosphate). Lysates were clarified by
centrifugation, and protein was quantified and analyzed by SDS–
PAGE. Gels were processed for Western blotting by using the
Ab1272 chicken IgY antibody directed against tbdn-1 (Gendron et
al., 2000). Expression of ASMA in RF/6A and MK/T-1 cells (Gend-
ron et al., 2001b) was analyzed by Western blot using an anti-
ASMA antibody (Sigma). VEGFR-2 Western blot analysis was
performed by using a polyclonal anti-VEGFR-2 antibody (Santa
Cruz Biotechnology).
Immunoprecipitation
Cell lysates for immunoprecipitation were prepared by using
TNB lysis buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 0.5% Brij 96)
supplemented with protease inhibitors and phosphatase inhibitors
as described above. Lysates were clarified by centrifugation, and
protein concentrations were quantified. For analysis of VEGFR-2
expression, VEGFR-2 was immunoprecipitated from RF/6A cell
lysates by incubation for 6 h to overnight at 4°C with 7.5 g of a
polyclonal anti-VEGFR-2 antibody (Santa Cruz Biotechnology).
Immune complexes and whole cell lysates were analyzed by
SDS–PAGE. Gels were processed for Western blotting analysis with
a different anti-VEGFR-2 antibody (Santa Cruz Biotechnology) than
that used for immunoprecipitation.
Recombinant cDNA Constructs and Proteins,
and Transfections
For assessing the effects of downregulating the level of tbdn-1
expression on capillary formation in vitro, IEM and RF/6A cells
were transfected by using lipofection with the vector pcDNA3.1/
Zeo (Invitrogen) alone, or with a construct of the pcDNA3.1/Zeo
vector harboring TBDN-1 cDNA nucleotide sequences 1–1413 in
an antisense orientation (ASTBDN-1). This latter ASTBDN-1 con-
struct was described previously and shown to block tbdn-1 protein
expression in IEM cells (Gendron et al., 2000). Two days after
transfection, cells were selected with Zeocin (Invitrogen). After
selection, 30 clones from each transfection were isolated with
cloning cylinders, expanded, and characterized. Stable IEM cell
transfectants and RF/6A clones were maintained in the presence of
75 and 100 g/ml of Zeocin, respectively.
Acetyltransferase Activity
For determination of acetyltransferase activity copurifying with
tbdn-1, tbdn-1 was immunoprecipitated by using the Ab1272
antibody from equal amounts of protein lysates of control IEM cells
or IEM cells showing reduced levels of tbdn-1 by overexpression of
ASTBDN-1 construct as previously described (Gendron et al.,
2000). Immunoprecipitates prepared using anti-tbdn-1 Ab1272
were next processed for acetyltransferase reactions in the presence
of [3H]acetyl-Co-enzyme A as described previously (Gendron et al.,
2000).
Capillary Outgrowth Assays
Capillary outgrowth of parental and transfected RF/6A cell
clones on Matrigel (Collaborative Biomedical Products, Bedford,
MA) was induced by 10 ng/ml of basic fibroblast growth factor
(bFGF) essentially as described (Gendron et al., 1996). Two days
after stimulation with bFGF, cells were transferred to Matrigel in
142 Paradis et al.
© 2002 Elsevier Science (USA). All rights reserved.
the presence of fresh bFGF. Relative capillary abundance was
quantitated by using methods previously described (Gendron et al.,
1996; Paradis and Gendron, 2000). Colonies of cells sprouting
capillary structures on Matrigel were photographed, and the num-
ber of sprouts per individual colony was counted. To account for
variation in colony sizes, the capillary abundance was expressed as
the number of capillaries per individual colony divided by the
approximate diameter of the colony. The diameters of individual
colonies were approximated by calculating the average of four
measurements evenly spaced around the circumference of each
colony. At least three separate capillary outgrowth assays were
performed in duplicate on several of the different RF/6A transfec-
tants and parental cells. Colonies of two control clones and two
ASTBDN-1 clones showing downregulation of tbdn-1 protein were
analyzed in larger numbers for more precise quantification of
relative capillary abundance. Results were expressed as mean of
relative capillary abundance  standard error of the mean (sem).
RESULTS
Tbdn-1 Is Expressed in Developing Mouse and
Human Vitreal Vasculature
In order to study the temporal dynamics and spatial
localization of tbdn-1 expression in the developing posterior
chamber ocular vasculature, immunolocalization of tbdn-1
protein was performed on specimens of developing mouse
eye. Our results revealed that tbdn-1 protein expression in
vitreal blood vessels appears to increase between embryonic
day (E) 13.5 of embryogenesis and postnatal day (P) 1 of
postnatal development (Figs. 1A–1D). Tbdn-1 expression
was also detected at P5 in the vitreous (Fig. 1E). The
embryonic vitreal blood vessels were negative when stained
with preimmune IgY, a negative control for the tbdn-1
antibody (see Fig. 1F). Hyalocytes scattered around the
vitreal vascular networks at the E16.5 and E18.5 stages also
expressed tbdn-1 at similar levels as found in endothelial
cells lining the vitreal blood vessels. These results indicate
that the mouse vitreal vasculature expresses tbdn-1 during
late gestation to early postnatal stages as the embryonic
vitreal vasculature matures during ocular development.
Tbdn-1 immunolocalization was also performed on a
human embryonic eye specimen to study the spatial local-
ization of tbdn-1 protein expression in the developing
human ocular vitreal vasculature. Analysis of a 14-week
human embryonic eye revealed that tbdn-1 was also ex-
pressed in human vitreal vessels (Figs. 1G and 1H). The
human embryonic vitreal vascular networks also expressed
the endothelial marker vWF (Fig. 1I) and were negative
when stained with preimmune IgY, a negative control for
the tbdn-1 antibody (Fig. 1J).
Analysis of Morphology of Accumulated Vitreal
Vasculature of Mice Lacking TGF-2
In a previous study, it was noticed that, in contrast to
wild type or heterozygote TGF-2/ mice, the posterior
chamber of TGF-2/ eyes show an accumulation of a
vitreal mass during late gestation (Saika et al., 2001). As
described above, since tbdn-1 is normally expressed in
developing vitreal cells, the TGF-2/ vitreal defect was
further characterized. In order to assess in more detail the
morphological changes of the posterior chamber tissues of
TGF-2/ eyes, light microscopy analysis of toluidine
blue-stained semithin sections and TEM of thin sections
were performed on E18.5 specimens (Figs. 2 and 3, respec-
tively). There was no observable difference in the morphol-
ogy of the vitreous between TGF-2/ and wild type eyes,
either at the level of the semithin toluidine blue sections or
the TEMs (not shown). Toluidine blue-stained semithin
sections clearly show that a large mass of vitreal and
vascular tissues is present in the posterior chamber in
TGF-2/ eyes, but not in TGF-2/ eyes (Fig. 2). TEM
(Fig. 3) revealed that vitreal vessel pericytes of TGF-2/
eyes appeared to retain a normal cellular morphology and
maintained tight cell–cell and cell–basal laminal adhesions
(Figs. 3A and 3C). In sharp contrast, TGF-2/ vitreal
vessels appeared to contain degenerated pericytes compared
with TGF-2/ eyes (Figs. 3B and 3D–3F). The pericytes in
TGF-2/ vessels show nuclear and cytoplasmic degenera-
tion with lack of normal organelles present, rare degener-
ated mitochondria, loss of cell-to-cell contact. and loss of
contact with the surrounding endothelial cell basal lami-
nae.
Expression Analysis of tbdn-1 and Blood Vessel
Markers in Accumulated Vitreal Vasculature of
Mice Lacking TGF-2
We next determined whether the expression of tbdn-1 in
the posterior chamber vasculature was affected in TGF-
2/ developing eyes. Using immunohistochemistry, we
observed a large decrement in tbdn-1 expression in the
accumulated blood vessels of the vitreal vasculature in
TGF-2/ developing eyes (Figs. 4D and 4H) as compared
with robust tbdn-1 expression in the wild type (Figs. 4A–
4C) and TGF-2/ heterozygous littermates (see Figs. 4E–
4G). This loss of tbdn-1 expression in TGF-2/ vitreal
vessels is observable at E16.5 (not shown) and E18.5 (Fig. 4)
stages. The cells surrounding the accumulated TGF-2/
vessels (presumably hyalocytes) also displayed a significant
decrease in tbdn-1 expression compared with hyalocytes in
wild type and TGF-2/ heterozygous eyes. Like the TGF-
2/ heterozygous eyes, the vitreal blood vessels in TGF-
2/ eyes express the endothelial marker vWF (Figs. 5A and
5B, respectively).
To further examine vessel organization and vascular
basal lamina integrity, the vitreal vasculature was stained
for collagen IV expression, which is a marker for the vessel
wall and labels the normal basal laminal components of
developing vitreal blood vessels (Sarthy, 1993). Vitreal
blood vessels in TGF-2/ eyes at the E18.5 (Fig. 5) stages
showed a well-defined collagen IV expression pattern ap-
pearing as rings of staining of the basal laminae in the
cross-sectioned vitreal vessels (Fig. 5C). Vitreal blood ves-
sels of TGF-2/ mice also expressed collagen IV, but the
staining for this marker in the TGF-2 null vitreal vessels
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FIG. 1. Tbdn-1 expression in the developing mouse and human ocular vitreal vasculature. (A) Tbdn-1 protein staining as revealed by red
stain in the developing mouse E13.5 eye (arrows indicate the early developing hyaloid network with in the vitreous body). (B) Tbdn-1 protein
staining (red) in the hyaloid vascular network of developing mouse E16.5 eye (arrows indicate the hyaloid vascular network within the
vitreous body, which is visibly larger at this stage than at the E13.5 stage). (C) Tbdn-1 protein staining (red) in cross-sections of vitreal blood
vessels in the E18.5 embryonic mouse eye (arrows indicate tbdn-1 positivity in the vitreal vascular endothelial cells). (D) Tbdn-1 protein
staining (red) in endothelial cells (arrowed) of a vessel tuft of the vitreal vasculature in the postnatal P1 mouse eye. (E) Tbdn-1 protein
staining in sections of vitreal vasculature in the postnatal P5 mouse eye (arrows indicate tbdn-1-positive endothelial cells lining a
longitudinally sectioned blood vessel on the posterior surface of the lens). (F) A section adjacent to that shown in (B) stained with
preimmune IgY, which is a negative control for the anti-tbdn-1 antibody staining, showing no staining. nr, neural retina; le, lens; vb,
vitreous body. (A), (B), (C), and (F) are shown at the same magnification (400), and scale bar in (C) equals 50 m. (D, E) Digitally magnified
slightly from 400 to 570 to better show sparsely distributed vessels at the E18.5–P5 stages, and scale bars equal 35 m. (G) Tbdn-1
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did not appear in well-defined rings in cross-sectioned
vessels and was disorganized and diffusely distributed
throughout the accumulated TGF-2/ vitreal tissue, sug-
gesting that the TGF-2/ vitreal vessels were disorganized
and that the basal laminae may be breaking down (Fig. 5D).
In order to assess the proliferative state of the vitreal
endothelial cells, we also compared the expression of
proliferating cell nuclear antigen (PCNA) and activated
P42/44MAPK expression in cross-sections of vitreal vessels of
TGF-2/ and TGF-2/ mice. Endothelial cells lining the
accumulating vitreal vessels of E18.5 TGF-2/ mice
showed a striking upregulation of both PCNA expression
and increased number of nuclei staining for the activated
P42/44MAPK compared with the vitreal vessels of TGF-2/
eyes (Figs. 5E–5H) at the same stage. These results indicate
that the endothelial cells lining the accumulating vitreal
FIG. 2. Morphological analysis of the vitreous in TGF-2/ mice. Toluidine blue-stained semithin sections of the vitreous of TGF-2/
(A, C) and TGF-2/ (B, D) eyes at E18.5 as indicated. The bottom panels show magnified areas of top panels. Orientation is the same for
all panels with the neural retina positioned at the bottom. hvm, hyaloid vascular mass; nr, neural retina; vb, vitreous body. Arrows indicate
the positions of vitreal blood vessels in each case.
protein staining of the hyaloid vessels within Cloquet’s canal in the developing human eye at approximately 14 weeks of gestation. (H)
Tbdn-1 protein staining in the tunica vasculosa lentis vessels of the same section as (G). (J) A section adjacent to (H) stained with
preimmune IgY, which is a negative control for the anti-tbdn-1 antibody staining. (I) a section adjacent to (H) stained with anti-vWF
antibody, which stains and labels endothelial cells (arrows indicate vWF-positive endothelial cells). Arrows in all panels indicate the
hyaloid and/or tunica vasculosa lentis blood vessels; vb, vitreous body; magnification of (G–J) is 1000, and scale bar in (G) equals 25 m
and is representative for all panels in (G–J).
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vessels of E18.5 TGF-2/ mice have a more proliferative
status than normal.
Strikingly, the vitreal vasculature of TGF-2/ mice
lacked staining for the pericyte marker alpha smooth
muscle actin (ASMA) compared with TGF-2/ heterozy-
gous vitreal vessels, which clearly showed cells staining
positive for ASMA at the E18.5 stages (Figs. 5I and 5J, see
arrows showing vessels lacking ASMA positivity in TGF-
2/ eye as compared with TGF-2/ heterozygotes).
Staining for another pericytes marker, CD13 (aminopepti-
dase N), was absent in the vitreal vasculature of TGF-2/
eyes compared with TGF-2/ heterozygous eyes, which
showed cells staining positive for CD13 at E18.5 stage (not
shown). These results indicate that the vitreal vessels of
TGF-2/ mice do not express markers that are normally
expressed by pericytes.
Reduction of tbdn-1 Expression Levels Augments
Capillary Formation of the Fetal Choroid–Retina
Endothelial Cell Line RF/6A
To examine the role of tbdn-1 expression in endothelial
cells in vitro, the spontaneously immortalized endothelial
cell line RF/6A derived from the choroid-retina of a rhesus
macaque fetus was used (Lou and Hu, 1987a,b). The expres-
sion of the definitive endothelial marker VEGFR-2 (Mill-
auer et al., 1993; Yamaguchi et al., 1993; Shalaby et al.,
1995) by the RF/6A cells was first confirmed to establish
that these cells maintain an endothelial phenotype. As
shown in Fig. 6 A, RF/6A VEGFR-2 expression is detectable
both by Western blotting and by immunoprecipitation
followed by Western blotting. The level of VEGFR-2 ex-
pressed by the RF/6A cells was low compared with HUVEC,
which served as a positive control. The different bands
recognized by the anti-VEGFR-2 antibody in RF/6A cell
extracts are likely due to differential glycosylation patterns,
as previously reported (Takahashi and Shibuya, 1997).
Moreover, the RF/6A cells did not express any detectable
levels of ASMA by Western blotting (Fig. 6B) using a
monoclonal antibody raised against an N-terminal decapep-
tide epitope (MCEEEDSTAL) of mouse ASMA that is 100%
identical with human ASMA and which has been used
previously to label ASMA in rhesus tissues (Schlatt et al.,
1993). Furthermore, stimulation of the RF/6A cells with
TGF-1 did not induce the expression of ASMA (Fig. 6B).
However, ASMA was readily detected in TGF-1-
stimulated MK/T-1 control cells (Fig. 6B). MK/T-1 cells are
a fibroblast line derived from corneal stromal cell cultures
which has been reported previously to upregulate ASMA
upon TGF- stimulation (Gendron et al., 2001b).
To examine the effect of downregulation of tbdn-1 levels on
endothelial cells in vitro, an antisense TBDN-1 cDNA con-
struct (ASTBDN-1) was used to decrease tbdn-1 expression in
the RF/6A choroid–retina endothelial cell line. In vitro trans-
lation methodology confirmed that the ASTBDN-1 construct
does not encode an irrelevant protein product which could be
toxic and cause nonspecific effects on cell function (data not
shown). In order to verify that the antisense TBDN-1 cDNA
blocked tbdn-1 protein expression, Northern blotting, West-
ern blotting, and acetyltransferase assays were performed on
lysates of RF/6A or IEM endothelial cell clones stably overex-
pressing ASTBDN-1 cDNA (Gendron et al., 2000). Several
RF/6A choroid–retina endothelial cell clones stably overex-
pressing ASTBDN-1 showed marked inhibition of tbdn-1
protein expression levels as compared with parental clones
and two control clones which expressed ASTBDN-1 vector
but showed no blockage of tbdn-1 protein production (Fig. 7A).
RF/6A choroid–retina endothelial cell clones stably overex-
pressing ASTBDN-1 also showed marked inhibition of tbdn-1
RNA expression levels as compared with control clones (data
not shown). We have also previously shown that stable over-
expression of ASTBDN-1 can effectively block tbdn-1 protein
expression in IEM embryonic endothelial cells (Gendron et al.,
2000). Furthermore, compared with parental cells, IEM clones
exhibiting reduced levels of tbdn-1 show a significant decrease
in acetyltransferase activity associated with immunoprecipi-
tates of tbdn-1 prepared from equal quantities of protein
lysates from these cells (see Fig. 7B for representative clone).
Since the growth properties of the RF/6A cell clones
expressing reduced levels of tbdn-1 did not appear different
from the parental cells, we used an in vitro capillary
formation assay on Matrigel (Gendron et al., 1996; Paradis
and Gendron, 2000) to test whether tbdn-1 could play a role
in the sprouting of capillary-like structures by these cells in
vitro. Similar to other endothelial cell lines, the RF/6A cells
can be induced by bFGF to form colonies that sprout
capillary-like structures on Matrigel (Gendron et al., 1996,
2001a; Paradis and Gendron, 2000). Several RF/6A cell
clones exhibiting reduced levels of tbdn-1 by overexpressing
ASTBDN-1 show a significant increase in their capillary
formation response compared to controls (see Figs. 8A and
8B for representative capillary colonies). The capillary-
forming response of the parental RF/6A cells, two represen-
tative RF/6A ASTBDN-1 clones showing downregulation of
tbdn-1 and one representative RF/6A clone transfected with
ASTBDN-1 but not showing downregulation of tbdn-1, was
quantified more precisely (Fig. 8C). Capillary colonies
formed by RF/6A ASTBDN-1 transfectant clones exhibiting
reduced levels of tbdn-1 show longer, more complex and
more abundant capillary sprouts (Fig. 8) than parental and
control clones as assessed by precise calculation of relative
capillary abundance (Paradis and Gendron, 2000). More-
over, reduction of tbdn-1 expression in the IEM embryonic
endothelial cell line using the same ASTBDN-1 cDNA
construct also was associated with more abundant capillary
sprouts than parental and control IEM clones (not shown).
These results indicate that tbdn-1 expression in endothelial
cells inhibits capillary formation.
DISCUSSION
Our results show that tbdn-1 protein is expressed by
developing vitreal blood vessels during late stages of em-
bryogenesis in the mouse. In contrast to wild type and
TGF-2/ mice, TGF-2/ mice show accumulation of a
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FIG. 3. Ultrastructural analysis of the vitreal vasculature in TGF-2/ mice. TEM of TGF-2/ vs TGF-2/ eyes at E18.5. Brackets in
(A) and (B) show partial areas of the vessels magnified in (C) and (D), respectively. (A, C) TGF-2/ vitreal vessels. Endothelial cells and
pericytes are flattened and extended in close apposition to adjacent cells and to the basal laminae (see white arrows in C indicating the tight
adhesion at the endothelial–pericyte basal lamina between endothelial cell (ec) and pericyte (pc). (B, D–F) Vitreal vessels of TGF-2/ eyes.
(B) A low-power view. (D–F) Higher power views to indicate the differences in morphology of TGF-2/ pericytes. Pericytes of TGF-2/
eyes show degeneration, cytoplasmic inclusion bodies, and loosening of contacts with adjacent endothelial cells (see white arrows in D
indicating the loose endothelial–pericyte apposition), and with basal laminae compared with TGF-2/ eyes. ec, endothelial cells; pc,
pericytes; rbc, red blood cell.
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large vitreal mass containing an increased number of ves-
sels and hyalocyte-like cells. This accumulation of the
vitreals vessels is accompanied by a loss in the expression of
tbdn-1 by these vitreal vessels. In contrast to the loss of
tbdn-1, our results show that accumulated vitreal vessels in
TGF-2/ eyes still express the endothelial marker vWF.
Thus, the loss of tbdn-1 in the accumulated vitreal blood
vessels of TGF-2/ eyes is not simply due to a loss of
endothelial cells from these vessels. Our TEM ultrastruc-
tural analysis also confirms that endothelial cells are
present in the vitreal blood vessels of TGF-2/ eyes. These
results suggest that removal of the TGF-2-mediated influ-
ence is responsible for the loss of tbdn-1 expression in the
accumulating TGF-2/ vitreal vessels. We do not know at
this time whether the effect of TGF-2 on tbdn-1 levels in
vitreal endothelial cells is direct or indirect. Recent evi-
dence (our unpublished results) indicated that mixtures of
extracellular matrix (ECM) components could directly regu-
late tbdn-1 levels, and we are in the process of determining
whether specific ECM components may be responsible for
tbdn-1 regulation. In the case of the TGF-2/ vitreal
vasculature, one might speculate that the absence of
FIG. 4. Tbdn-1 expression analysis in the vitreal vasculature in wild type, TGF-2/, and TGF-2/ embryonic mouse eyes. Tbdn-1
protein expression in vitreal vessels at E18.5. Tbdn-1 protein expression, as revealed by red stain, in three separate examples of vitreal
vasculature of wild type eyes (A–C), of TGF-2/ eyes (E–G), and in two representative examples of TGF-2/ eye (D, H; arrows indicate
blood vessels in all panels). The expression level of tbdn-1 in vitreal vessel endothelial cells in wild type eyes is the same as that observed
in TGF-2/ eyes. In sharp contrast to wild type and TGF-2/ eyes, the vitreal blood vessels in TGF-2/ eyes do not show expression
of tbdn-1 protein (D, H). (A–H) The same magnification. (I, J) Also at the same magnification as (A–H), are adjacent sections stained with
Verhoeff’s elastic stain (red blood cells stain gold–yellowish and highlight the blood vessels) from TGF-2/ (I) and TGF-2/ (J) eyes. The
Verhoeff’s stained panels are provided here in order to more clearly indicate the positions and relative morphology of blood vessels in the
sections of TGF-2/ eyes stained with anti-tbdn-1 antibody shown in (D) and (H). Le, lens; vcm, vitreal cell mass; vb, vitreous body; arrows
in all panels indicate the positions of vitreal blood vessels.
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FIG. 5. Endothelial vascular wall marker analysis in the vitreal vasculature in TGF-2/ mice. Endothelial marker vWF expression (black stain,
arrowed) is present in vitreal vasculature of both TGF-2/ (A) and TGF-2/ (B) mice. Collagen IV expression in vitreal tissue of TGF-2/ (C)
and TGF-2/ (D) mice. Collagen IV stains the vascular wall basement membranes in the TGF-2/ and TGF-2/ vitreal vasculature (brown
stain; arrowed). However, in TGF-2/ vitreous, collagen IV stains both disorganized vascular wall basement membrane material and is also
expressed diffusely throughout the accumulated vitreal tissue (brown stain; arrows indicate blood vessels). Nuclear expression of PCNA (dense
nuclear brown stain, arrowed) was upregulated in endothelial cells in cross-sections of vitreal vessels of TGF-2/ (F) as compared with the low
level of PCNA in vitreal vessels of TGF-2/ mice (E). Nuclear expression of phosphorylated p42/44MAPK (dense nuclear brown stain, arrowed)
was upregulated in endothelial cells in cross sections of vitreal vessels of TGF-2/ (H) as compared with the low level of phosphorylated
p42/44MAPK in vitreal vessels of TGF-2/ mice (G). ASMA expression (red stain) in cross-sections of vitreal vessels of TGF-2/ (I) and TGF-2/
(J) mice. The abnormal vitreal blood vessels in TGF-2-/ eyes do not express ASMA (J). (A–H) Shown at the same magnification. (I) is shown
at the same magnification as (J). The bar in (B) of 25 mm equals 50 m for (A–H). The bar in (J) of 35 mm equals 35 m for (I) and (J) (1000). nr,
neural retina; le, lens; arrows in all panels indicate the positions of vitreal blood vessels.
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TGF-2 regulates tbdn-1 levels indirectly through distur-
bances in expression patterns of ECM components. Colla-
gen IV, which is a normal component of the vascular basal
lamina (Sarthy, 1993), was used here as a vessel wall
marker. Collagen IV showed a diffuse pattern of expression
throughout the accumulated vitreal tissue in the TGF-2/
eyes compared with controls, in which collagen IV expres-
sion was concentrated only in the normal vascular basal
lamina. The diffuse expression pattern of collagen IV in the
vitreal tissue of TGF-2/ eyes is consistent with a disor-
ganization of the vessels and breakdown of vessel basal
laminae. Alternatively, collagen IV expression may be more
disorganized because the TGF-2/ vessels are developing
too rapidly for the formation of a defined basal membrane.
Whether or not collagen IV is a candidate ECM molecule
that might regulate tbdn-1 expression remains to be inves-
tigated.
Hyalocytes scattered around the vitreal vascular net-
works at E16.5–E18.5 stages also expressed tbdn-1. Hyalo-
cytes are thought to share lineage characteristics with
monocyte/macrophages but are also known to express
markers present on endothelial cells, such as binding sites
for the endothelial-reactive lectin Griffonia simplicifolia
(Lazarus and Hageman, 1994). Tbdn-1 expression by hyalo-
cytes is consistent with the endothelial and monocytic
characteristics of hyalocytes since tbdn-1 is also expressed
in cells of myeloid origin in the bone marrow and in yolk
sac endothelial and hematopoietic cells during early em-
bryogenesis (Gendron et al., 2000). The vitreal cells in
accumulating TGF-2 null eyes show suppression of tbdn-1
expression. Besides endothelial cells expressing vWF, cells
accumulating in the vitreous of TGF2 null mice could be
either endothelial cells expressing undetectable levels of
vWF, hyalocyte-like cells, or macrophages. However, the
accumulating cells are unlikely to be macrophages since no
staining for the macrophage marker F4/80 was observed in
TGF-2 null vitreous either at E13.5 (Saika et al., 2001) or at
E18.5 (data not shown). TGF2 could influence the differ-
entiation and maturation of these cells and this may impact
on their expression of markers. The phenotype of the
hyaloid-like cells in TGF-2 null eyes will require further
investigation.
Our results indicate that vitreal blood vessels of TGF-
2/ eyes contain degenerating pericytes. Pericytes in
vitreal vessels of TGF-2/ eyes showed degeneration,
cytoplasmic inclusions, and lack of contacts with adjacent
cells and with surrounding basal laminae compared with
TGF-2/ eyes. TGF-2/ eyes show decreases in ASMA
and CD13-aminopeptidase N-positive staining (markers for
pericytes) in the persisting vitreal vasculature, while TGF-
2/ eyes clearly contained ASMA and CD13-positive
cells. These results further support a conclusion that peri-
cytes are degenerating in TGF-2/ vitreal vessels. Since
TGF- is known to induce expression of ASMA in pericyte
cell lines in vitro (Verbeek et al., 1994), it could be argued
that loss of ASMA does not really reflect loss of pericytes in
the TGF-2-deficient environment but rather only loss of
ASMA expression by existing pericytes. Our ultrastructural
evidence showing degeneration of the pericytes in the
vitreal vasculature of TGF-2/ eyes suggests that the
existing pericytes are unhealthy and may not retain normal
FIG. 6. RF/6A choroid retina cells retain expression of an endo-
thelial specific marker and do not display vascular smooth muscle
cell characteristics. (A) Western blot analysis of VEGFR-2 expres-
sion in whole cell lysates of RF/6A cells (RF/6A lane, 50 g of
protein loaded) and of HUVEC (10 g of protein loaded). VEGFR-2
immunoprecipitation/Western blot analysis of RF/6A cell lysate
(RF/6A [ip], lane; 1000 g of protein was immunoprecipitated). (B)
Western blot analysis of alpha smooth muscle actin (ASMA)
expression in extracts of RF/6A cells (100 g of protein loaded)
nontreated (RF/6A) or stimulated with TGF- for 72 h [RF/6A()]
compared with an extract (20 g of protein loaded) of a mouse
corneal stromal cell line stimulated with TGF- for 48 h [MK/T-
1()].
FIG. 7. Overexpression of antisense TBDN-1 cDNA blocks
tbdn-1 protein expression in endothelial cell lines in vitro. (A)
Expression analysis of tbdn-1 protein in 50 g of whole cell lysate
of the untransfected rhesus RF/6A choroid–retina endothelial cell
line (Parental), in two control clones of RF/6A cells stably express-
ing a TBDN-1 antisense cDNA fragment but not showing down-
regulation of 69 kDa tbdn-1 (Antisense 1 and 2) and in three clones
of RF/6A cells stably expressing TBDN-1 antisense cDNA fragment
showing downregulation of 69 kDa tbdn-1 (Antisense 3, 4, and 5),
as indicated. The 69-kDa tbdn-1 protein band is indicated by the
arrow. (B) Acetyltransferase activity analysis of tbdn-1 immunopre-
cipitates prepared from equal protein amounts of whole cell lysates
of the IEM cell line (Parental), and in IEM cells stably overexpress-
ing a TBDN-1 antisense cDNA fragment (anti-sense), assayed at the
indicated pH. The acetylated 69-kDa band (indicated by the arrow),
possibly corresponding to tbdn-1, is present at lower levels in
antisense cells compared with the parental cells.
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function. The decreased expression of the pericyte marker
CD13 (Alliot et al., 1999) in TGF-2/ vitreal vasculature
also supports this hypothesis. Interestingly, ASMA was
detected at normal levels in pericytes of blood vessels in
various head regions of the TGF-2/ embryos. This obser-
vation indicates that the decrease in ASMA-positive cells in
the accumulated vitreal vasculature in TGF-2/ eyes is
unlikely due to a global downregulation of ASMA in peri-
cytes resulting from the lack of TGF-2. TGF1 or TGF3
may have a similar role as TGF-2 in other tissues. How-
ever, in the case of the vitreal vasculature, loss of TGF-2
alone is sufficient to lead to accumulation of the abnormal
vitreal vasculature. Physical properties of blood vessels may
also impact upon the functional contacts of the cells
composing them. Formation of blood vessels may be regu-
lated at a paracrine level through local signaling contacts at
pericyte–endothelial junctions (CIDEP; Wakui, 1992). Pre-
vious studies have shown that physical contacts between
endothelial cells and pericytes are required for production
of active TGF- by these cells (Antonelli-Orlidge et al.,
1989; Sato and Rifkin, 1989). The importance of contacts
between endothelial cells and pericytes for proper blood
vessel formation and endothelial integrity has been demon-
strated by gene targeting studies in mice. Mice lacking
either PDGF-B or its receptor PDGFR- display defective
blood vessel development characterized by lack of peri-
cytes, endothelial hyperplasia, and abnormal shape and
ultrastructure of endothelium (Hellstrom et al., 2001).
TGF-1, TGF-2, and TGF-3 exhibit similar activities on
cells in vitro, but in vivo their pattern of expression is
distinct and mice deficient for the different TGF- isoforms
exhibit distinct phenotypes ranging from multiple develop-
mental malformations to less severe lung and palate defects
(Piek et al., 1999; Dunker and Krieglstein, 2000). TGF-s
exert an inhibitory influence on the in vitro proliferation
and migration of endothelial cells (Antonelli-Orlidge et al.,
1989; Sato and Rifkin, 1989). Gene targeting studies have
indicated that TGF-1 plays a role in regulating endothelial
FIG. 8. Inhibition of tbdn-1 expression augments capillary formation of RF/6A choroid–retina endothelial cells in a Matrigel capillary
formation assay. Capillary colonies formed by RF/6A clones overexpressing antisense TBDN-1 cDNA and displaying suppression of tbdn-1
protein expression show longer, more complex, and more abundant capillary sprouts than parental and control cells. Representative
phase-contrast images of capillary colonies are shown in (A) (parental colony) and (B) (AS3 colony [tbdn-1 suppressed]). Results are displayed
in the histogram as relative capillary abundance (mean  sem) in the histogram (C). Levels of tbdn-1 expression for each of these clones as
assessed by Western blot analysis are displayed in Fig. 7.
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cell differentiation during development (Dickson et al.,
1995). The overexpression of active TGF-1 in the posterior
chamber of the eye under the control of a lens-specific
promoter blocks vitreal vessel growth (Srinivasan et al.,
1998). Moreover, there is evidence that TGF-2 present in a
heparin-bound fraction in aqueous humor in the adult eye
can inhibit endothelial cell growth and in vitro angiogen-
esis (Hayasaka et al., 1998). Furthermore, TGF- isoforms
are disregulated in proliferative diabetic retinopathy, a
disease which often progresses to stages of extensive retinal
and vitreal neovascularization (Spranger et al., 1999). Pre-
vious studies indicated that eye developmental defects in
TGF-2/ mice include ocular hypercellularity and malfor-
mation of the cornea and anterior segment (Sanford et al.,
1997; Saika et al., 2001). The phenotype of the TGF-2/
vitreous is consistent with evidence that TGF- plays an
important role in regulating endothelial cell growth and
differentiation (reviewed in RayChaudhury and D’Amore,
1991). Our results revealing that TGF-2/ vitreal vessels
are more numerous and contain degenerated pericytes is
consistent with an inhibitory role for TGF-2 in vitreal
blood vessel endothelial growth. Our results demonstrating
the upregulation of PCNA and increased levels of activated
P42/44MAPK in the nuclei of TGF-2/ vitreal endothelial
cells indicate a more proliferative state of these endothelial
cells (Hall et al., 1990; Paradis and Gendron, 2000; Dhanas-
ekaran and Premkumar Reddy, 1998). Our finding that the
accumulated blood vessels of the vitreal vasculature in
TGF-2/ mice show a significant decrease in the expres-
sion of tbdn-1 is consistent with a hypothesis that tbdn-1
may play a role in a TGF-2-related pathway in regulating
vasculogenesis and/or angiogenesis events in the maturing
vitreal vasculature. Our data would suggest an inhibitory
role for tbdn-1 in TGF-2 control of vitreal vascular growth,
since tbdn-1 is normally expressed as the vitreal vascula-
ture matures by remodeling and pruning while its expres-
sion is decreased in the accumulating TGF-2/ vitreal
vasculature. Similarly, we have observed the suppression of
normal retinal vascular tbdn-1 expression in retinal vessel
proliferation in proliferative diabetic retinopathy (Gendron
et al., 2001a).
In order to address the hypothesis that tbdn-1 plays an
inhibitory role in vitreal blood vessel growth, we used an in
vitro model system to recapitulate vitreal blood vessel
formation. We utilized the RF/6A cell line, originally iso-
lated from choroid–retina tissue of a rhesus macaque fetus
(Lou and Hu, 1987a,b) for modeling capillary formation of
fetal posterior chamber endothelial cells. The tissue of
origin and cellular phenotype of the RF/6A cell line was
taken into consideration for these studies. The tunica
vasculosa lentis aspect of the vitreal vasculature is thought
to be composed of a mixture of blood vessels originating
both from the hyaloid artery and from the choriocapillaris
(reviewed in Silbert and Gerwood, 2000). Since the RF/6A
cells originate from fetal choroid–retinal tissue and have
been previously reported to retain endothelial characteris-
tics, we surmised that the RF/6A cells might most closely
approximate embryonic vitreal vascular endothelial cells.
Furthermore, no other such cell lines are currently avail-
able. We first verified that the RF/6A cell line retained an
endothelial phenotype, as reported originally (Lou and Hu,
1987a,b). Our results demonstrate that the RF/6A cell line
indeed does retain the expression of endothelial markers
such as VEGFR-2 tyrosine kinase, a definitive endothe-
lial specific marker required for endothelial cell growth
and development and which has been demonstrated to
be upregulated during pathological retinal neovasculariza-
tion (Millauer et al., 1993; Yamaguchi et al., 1993; Shalaby
et al., 1995; Robbins et al., 1998; Hammes et al., 1998).
Furthermore, neither unstimulated nor TGF--stimulated
RF/6A cells express ASMA, a marker for pericytes and
vascular smooth muscle cells (VSMC) upregulated upon
TGF- stimulation of MK/T-1 corneal fibroblast cells
as well as perivascular cells (Sawtell and Lessard, 1989;
Gendron et al., 2001b; Verbeek et al., 1994). These char-
acteristics indicate that RF/6A cells display an endo-
thelial cell phenotype rather than a perivascular cell phe-
notype.
We have previously described that tbdn-1 expression is
downregulated during capillary formation of IEM endothe-
lial cells and RF/6A choroid–retina endothelial cells, sug-
gesting that expression of tbdn-1 may act to dampen capil-
lary formation (Gendron et al., 2000, 2001a). An antisense
TBDN-1 construct was used to assess the effects of reducing
tbdn-1 expression on RF/6A capillary formation in vitro. As
expected, the expression of ASTBDN-1 cDNA resulted in
reduction of tbdn-1 protein expression as well as reduction
of acetyltransferase activity present in tbdn-1 immunopre-
cipitates. These results confirm that the acetyltransferase
activity associated with the anti-tbdn-1 antibody Ab1272 is
specific for tbdn-1. Inhibition of tbdn-1 protein levels by
expression of ASTBDN-1 significantly augmented capillary
formation of both the RF/6A and IEM endothelial cell lines.
These results indicate a role for tbdn-1 in dampening
capillary formation. Based on these data, one might specu-
late about the functional role of tbdn-1 expression in the
developing vitreal vasculature. The remodeling and pruning
events which shape the vitreal vasculature late in embryo-
genesis precede a complete regression of the vitreal vascu-
lature during early postnatal stages (Lang et al., 1993; Yang
et al., 1996, Zhu et al., 1999; Mitchell et al., 1998; Ito and
Yoshioka, 1999; Ash and Overbeek, 2000). These events
likely require and include a dampening influence on vitreal
capillary formation during late embryogenesis. TGF-2 and
tbdn-1 may provide this dampening influence on vitreal
capillary formation in late embryogenesis. The mecha-
nisms by which TGF-2 and tbdn-1 might interact in this
process remain to be determined.
Changes in the state of ocular pericytes are known to be
associated with vasculopathy in eye diseases in humans.
Pericyte death, thickening of the basement membrane, and
changes in ECM expression pattern in proliferative diabetic
retinopathy have been described in previous studies
(Yanoff, 1966; Bloodworth and Epstein, 1967; Cogan and
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Kuwabara, 1967; Addison et al., 1970; Ashton, 1974; Speiser
et al., 1968; Podesta et al., 2000). Our results raise the
possibility that degenerative changes in pericytes and
changes in ECM protein and tbdn-1 expression patterns
may also be important for diseases affecting the developing
vitreal vasculature. The vitreal vasculature of TGF-2/
mice mimics these defects in addition to displaying a
reduction in tbdn-1 levels. Similarly, recent results show
that tbdn-1 levels are markedly suppressed during neovas-
cularization in proliferative diabetic retinopathy (Gendron
et al., 2001a). Our immunohistochemical analysis of a
human 14-week embryonic eye revealed that tbdn-1 is
expressed in human hyaloid and tunica vasculosa lentis
vessels. In human, the hyaloid and tunica vasculosa lentis
vasculature regresses prenatally at approximately 24 weeks
(Zhu et al., 1999). Therefore, the expression of tbdn-1 at 14
weeks of gestation in these vessels raises the possibility
that tbdn-1 expression may also play a role in regulating
maturation by dampening formation of the hyaloid and
tunica vasculosa lentis vasculature in human. Failure of
regression of the vitreal vasculature in PFV in humans can
lead to vision loss and blindness (Boeve et al., 1990;
Steichen-Gersdorf et al., 1997; Castillo et al., 1997; Gold-
berg, 1997; Silbert and Gurwood, 2000). Interestingly, there
is a high frequency of PFV and cataracts in p53-deficient
mice (Reichel et al., 1998). The persistent hyaloid and
tunica vasculosa lentis vasculature of the TGF-2/ phe-
notype and the vitreal phenotype of PFV is similar. Further-
more, both the TGF-2 null eye phenotype and human PFV
involve anterior ocular segment defects, such as corneal
abnormalities (Saika et al., 2001, Castillo et al., 1997). It is
thus conceivable that disturbances and/or disregulation in
the TGF-2 and/or tbdn-1 pathway are also involved in the
pathophysiology of PFV. These possibilities are currently
being explored in our laboratories.
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